Page 24«..1020..23242526..3040..»

Ozempic and Mounjaro may also lower your risk of obesity-linked cancer – National Geographic

Posted: July 21, 2024 at 2:38 am

More evidence suggests that medications such as Ozempic and Mounjaro, originally developed for diabetes and then approved for obesity, have benefits that go beyond these conditions. Those include lower risk of 10 cancers, protection against heart and kidney diseases, and reduction in systemic inflammation,according to recently published research.

This drug class, known as GLP-1 agonists, includes semaglutideapproved as Ozempic for type 2 diabetes and Wegovy for obesityand tirzepatideapproved as Mounjaro for diabetes and Zepbound for obesity. Some of these protective effects likely result from patients weight loss when taking these medications, but the drugs appear to have othereffects that improve healthindependent of the weight loss.

The cardioprotective effect of semaglutide observed in people with obesity developed within months of drug initiation, well before meaningful weight loss had been achieved in most trial participants inone 2022 trial, Daniel Drucker, a physician-scientist at the Lunenfield-Tanenbaum Research Institute at Mt. Sinai Hospital in Toronto, states in a commentary publishedThursday in Science. The initial chapter of GLP-1 innovation focused on glucose control, and later, weight loss, he writes. Subsequent waves seem likely to improve health outcomes in people with a range of chronic disorders.

Indeed, a recent studyinJAMA Network Openis the first to suggest that even protection from certain cancers could be among the ways these drugs can help improve health.People with obesityhave a higher risk of developing 13 cancers, and the new research found a reduced risk for 10 of these cancers in patients with type 2 diabetes who were prescribed a GLP-1 agonist drug, compared to just insulin.

While the study was large, with more than 1.6 million patients from the United States, it has multiple limitations that warrant cautious optimism, says William Murphy, a cancer immunologist at the University of California Davis School of Medicine who studies obesitys impact.

Follow this link:
Ozempic and Mounjaro may also lower your risk of obesity-linked cancer - National Geographic

Posted in Diabetes | Comments Off on Ozempic and Mounjaro may also lower your risk of obesity-linked cancer – National Geographic

Diabetes drug may make lung cancer treatment more effective – Futurity: Research News

Posted: July 21, 2024 at 2:38 am

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A medication used to treat diabetic neuropathy may make chemotherapy treatments more effective for patients with lung cancer, according to a new study.

Despite surgical and chemotherapy treatment, more than 50% of non-metastatic, non-small lung cancer patients see recurrences, in large part because of drug-resistant cancer cells.

Researchers have identified a way to make these cells more susceptible to chemotherapy, says study author Jussuf Kaifi, a thoracic surgeon at the University of Missouri Health Care and an assistant professor of surgery at the universitys School of Medicine.

Traditional treatments for lung cancer, including chemotherapy, often have little to no effect on the cancer because of drug resistance, Kaifi says.

It is a major cause of mortality in patients, so finding ways to circumvent drug and chemotherapy resistance is vital to improving patient outcomes.

The study examined 10 non-small cell lung cancer tumors, half of which were identified as drug resistant. The drug-resistant tumors showed overexpression of a certain enzyme, AKR1B10. When treated with the diabetic neuropathy medication, epalrestat, the tumors became less drug resistant, causing their sensitivity to chemotherapy to significantly increase.

Epalrestat is available in several countries and well-tolerated by patients, but it is not yet approved for use by the Food and Drug Administration in the United States. The medication is currently in high-level clinical trials as part of the FDAs approval process. If given FDA approval, epalrestat could be fast-tracked as an anti-cancer drug for lung cancer patients.

In general, developing new drugs for cancer treatment is an extremely lengthy, expensive and inefficient process, Kaifi says.

In contrast, repurposing these drugs to other diseases is much faster and cheaper. In view of overcoming drug resistance, epalrestat can rapidly be advanced to the clinic to improve cure rates in lung cancer patients.

The research appears in Clinical Cancer Research.

Source: University of Missouri

Read the rest here:
Diabetes drug may make lung cancer treatment more effective - Futurity: Research News

Posted in Diabetes | Comments Off on Diabetes drug may make lung cancer treatment more effective – Futurity: Research News

The #1 Swap That May Decrease Your Risk of Heart Disease and Diabetes, According to a New Study – EatingWell

Posted: July 21, 2024 at 2:38 am

Through the years, nutrition recommendations have changed numerous times as evidence from the research mounted in one direction or the other. For example, we used to think that the cholesterol in the foods we eat added to the cholesterol in our bodies. We now know that if it affects it at all, its minimal.

And remember the no-fat fad? We now know that some fat in our diets is necessary.

But research on what types and how much fat is necessary is still not totally conclusive. For example, there is evidence that some types of saturated fat arent as harmful as other typeslike the kind in cheese and eggs compared to those in highly processed foods. Or perhaps its actually other components in the food that protect us from any harmful effects of the saturated fat in the foodmore research to come. Either way, this doesnt mean you should eat unlimited amounts of them.

In fact, a new study published on July 11, 2024, in Nature Medicine looked at what happens when saturated animal fats (like butter) are swapped out for plant-based unsaturated fats (like olive oil). Lets see what they found.

This study was conducted differently from typical studies in that it used four different study cohorts instead of one. From the first cohort, which was an original study, researchers established what they called a multi-lipid score (MLS). There are over 100 different types of lipids. Lipid levels are tested via bloodwork. In this study, called the Dietary Intervention and Vascular function (DIVAS) trial, researchers took 113 participants and randomly split them in half. For 16 weeks, one group ate a diet high in saturated animal fats, while the other group ate a diet rich in plant-based unsaturated fats. What they found in this study was that higher MLS correlated with healthier blood fat profiles, higher intakes of plant-based unsaturated fats and lower intakes of animal-based saturated fats.

Researchers then computed participants multi-lipid scores in three other large, long-term studies that had previously been done to see if higher MLS correlated with reduced risk of heart disease and type 2 diabetes. These studies were called the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study, the Nurses Health Study (NHS and NHSII), and the PREDIMED trial.

These three other studies included large cohorts of participants and initially healthy individuals who were followed for several years. This gave researchers a chance to see what participants diets were composed of, what their lipid profiles wereso they could compute multi-lipid scores based on their blood levelsand whether or not they ended up with heart disease and/or diabetes.

What researchers found was that participants with a higher MLSwhich indicates a diet containing lower levels of saturated fat and higher levels of unsaturated fatshad a substantially reduced risk of developing cardiometabolic diseases, including heart disease and diabetes.

Specifically, in the EPIC-Potsdam study, participants with higher MLS had an estimated 32% lower risk of heart disease and 26% lower risk of type 2 diabetes.

The NHS cohort suggests that improving dietary fat quality over 10 years was associated with about a 43% lower risk of developing diabetes.

In considering the PREDIMED study, researchers looked at participants who had low MLS at the beginning of the study, indicating a diet high in saturated fat and low in unsaturated fats. They wanted to know if improving diet qualityspecifically, switching to a Mediterranean diet eating patternwould help prevent disease. They found that switching from a diet high in saturated fat to a Mediterranean diet eating style, which includes lots of unsaturated fats, helped prevent the onset of diabetes.

According to the Centers for Disease Control and Prevention, heart disease is the No. 1 cause of death and disability globally, including in the U.S. And diabetes is a risk factor for heart disease, especially when blood sugar levels are not well-managed.

A Mediterranean diet eating pattern has been shown to have many benefits, including reducing the risk of heart disease, stroke and type 2 diabetes. Engaging in this way of eating also reduces cognitive decline, bone loss and inflammation. Altogether, following a Mediterranean diet may help you live longer.

The Mediterranean diet includes lots of fruits, vegetables, nuts, seeds, lean proteins, legumes, whole grains and healthy fats. If youre not ready to jump into a full Mediterranean diet eating style, start with simple swaps by trading foods you typically eat that are high in saturated fat with foods that are high in unsaturated fats. For example, instead of slathering butter onto your toast, swap the butter with mashed avocado or peanut butter. Instead of butter and sour cream on your baked potato, try a drizzle of garlic-infused olive oil and a dollop of plain Greek yogurt. Switch out one dinner with red meat each week for a heart-healthy salmon meal. Have a handful of nuts in place of chips for your snack.

This study adds to the evidence suggesting that replacing foods high in saturated fats with foods high in heart-healthy unsaturated fats may help reduce the risk of heart disease and diabetes. A Mediterranean diet eating pattern has consistently been shown to reduce inflammation and disease risk. Instead of trying to overhaul your routine, simply swap some foods that are high in saturated fat with foods that are high in unsaturated fat, like nuts and nut butters, seeds, oils and seafood. Small swaps will eventually add up to big changes that may help reduce your risk of disease, improve your quality of life and increase your chances of living longer.

Excerpt from:
The #1 Swap That May Decrease Your Risk of Heart Disease and Diabetes, According to a New Study - EatingWell

Posted in Diabetes | Comments Off on The #1 Swap That May Decrease Your Risk of Heart Disease and Diabetes, According to a New Study – EatingWell

Cancers with an Exceptional Cause – The Scientist

Posted: July 21, 2024 at 2:38 am

Cancers typically arise when cells accumulate mutations in their DNA that prevent them from keeping cell division in check.1 However, for some tumor types, researchers have struggled to find mutations, leading scientists to question their causes.2 Now, in a study published in Nature, researchers found that short-lived epigenetic changes can permanently alter gene expression and trigger cancer.3 While most cancers develop following mutations, their findings suggest that a few tumor types might deviate from this rule.

For years, Giacomo Cavalli, a geneticist at the French National Centre for Scientific Research, and his colleagues have studied the role that epigenetic factors called Polycomb proteins play in cancer.4 These proteins form complexes that wind up chromatin and switch off genes that promote cell division. The team previously found that mutations in Polycomb factors cause chromatin unraveling, which cascades into cell proliferation and cancer initation.5 They wondered whether they could achieve the same effect by temporarily switching Polycomb genes off.

To test their hypothesis, they turned to the fruit fly, Drosophila melanogaster; the species has only one copy of each gene involved in the Polycomb machinery, making it easier to disrupt the system. Polycomb proteins play key roles during development by influencing the timing of cell differentiation. Cavalli and his team studied the impact of losing this epigenetic control on early, larval structures called imaginal discs. Using a temperature-sensitive RNA interference system, they exposed the discs to warmer temperatures for 24 hours, which temporarily turned off the Polycomb genes for two days.

They very nicely showed that with this transitory system they could switch off this development gene briefly, switch it back on, and that was enough to trigger tumorigenesis, said Douglas Hanahan, a cancer biologist at the Swiss Federal Institute of Technology Lausanne who was not involved with the work.

Continue reading below...

To ensure that genetic mutations didnt trigger these cancers, the team sequenced the cancer cells alongside healthy controls. You do have mutations, Cavalli said, but there is no difference in the quantity of the mutational events in the cancer samples compared to the control samples.

To confirm that these mutations did not kickstart the cancers, the team tracked the position of tumor cells in the imaginal discs. They hypothesized that if mutations gave rise to a cancer, they would have started with a single troublemaker cell whereas epigenetic reprogramming would have stirred up rebellion of the whole tissue. To spot fast-dividing tumor cells, they stained the imaginal discs with 5-ethynyl-2-deoxyuridine (EdU), a dye that takes the place of thymine during DNA replication.6 EdU was ubiquitous throughout the imaginal discs, pointing to tissue-wide epigenetic reprogramming as the cancer culprit.

Cavallis team found that temporarily knocking down Polycomb factors fired up genes that they typically repress. This led to a surge in Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling, which promotes cell proliferation.7 JAK-STAT activation also caused a domino effect, flipping the switch on other genes linked to cancer. This included booting up the zinc finger homeodomain-1 gene, which suppresses developing cells from differentiating and ultimately slows down growth.8

According to Cavalli, the study raises questions about how often epigenetic alterations drive tumor formation. It can be more common than we think, Cavalli said. When we sequence cancers and find mutations, we typically do so when the cancer is already developed. However, its possible that epigenetic forces transformed the initial cells, he suggested. Indeed, this might apply to some brain cancers in children.9 There is no evidence for a blizzard of mutations in these pediatric tumors, and yet there are tumors, Hanahan said, adding that these cancer types could be fertile grounds to explore epigenetic triggers in humans.

Continue reading below...

Researchers arent sure which factors trigger these short-lived, cancer-causing epigenetic changes. Inflammation is a major promoter of tumor initiation, Hanahan said. Immune cells might secrete a milieu of chemicals signals that disrupt epigenetic control of gene expression within cells and prompt cancers, he suggested.

Looking ahead, Cavalli aims to move away from the fruit fly to study epigenetic drivers in mammalian models that have an immune response and vasculatureboth of which influence cancer evolutionthat better reflect those of humans.

Cavalli noted that some researchers are developing epigenetic cancer therapies, which aim to reverse cancer cells instead of killing them.10 Further research into the role of epigenetics in tumor initiation could help drug developers work out how to subdue these long-overlooked cancer drivers.

1. Hanahan D. Hallmarks of cancer: New dimensions.Cancer Discov. 2022;12(1):31-46. 2. McDonald OG, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.Nat Genet. 2017;49(3):367-376. 3. Parreno V, et al. Transient loss of Polycomb components induces an epigenetic cancer fate.Nature. 2024;629(8012):688-696. 4. Parreno V, et al. Mechanisms of Polycomb group protein function in cancer.Cell Res. 2022;32(3):231-253. 5. Loubiere V, et al. Coordinate redeployment of PRC1 proteins suppresses tumor formation during Drosophila development.Nat Genet. 2016;48(11):1436-1442. 6. Flomerfelt FA, Gress RE. Analysis of cell proliferation and homeostasis using EdU labeling. In: Bosselut R, S. Vacchio M, eds. T-Cell Development.Method Mol Biol. 2016;1323:211-220. 7. Zoranovic T, et al. Regulation of proliferation, cell competition, and cellular growth by the Drosophila JAK-STAT pathway.JAK-STAT. 2013;2(3):e25408. 8. Leatherman JL, DiNardo S. Zfh-1 controls somatic stem cell self-renewal in the Drosophila testis and nonautonomously influences germline stem cell self-renewal.Cell Stem Cell. 2008;3(1):44-54. 9. Jenseit A, et al. EZHIP: A new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.Acta Neuropathol. 2022;143(1):1-13. 10. Miranda Furtado CL, et al. Epidrugs: Targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14(12):1164-1176.

Go here to read the rest:
Cancers with an Exceptional Cause - The Scientist

Posted in Epigenetics | Comments Off on Cancers with an Exceptional Cause – The Scientist

PRC2-AgeIndex as a universal biomarker of aging and rejuvenation – Nature.com

Posted: July 21, 2024 at 2:38 am

Moqri, M. et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 186, 37583775 (2023).

Moqri, M. et al. Validation of biomarkers of aging. Nat. Med. 30, 360372 (2024).

Jylhava, J., Pedersen, N. L. & Hagg, S. Biological age predictors. EBioMedicine 21, 2936 (2017).

Article PubMed PubMed Central Google Scholar

Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat. Rev. Genet. 19, 371384 (2018).

Article PubMed CAS Google Scholar

Dabrowski, J. K. et al. Probabilistic inference of epigenetic age acceleration from cellular dynamics. Preprint at bioRxiv https://doi.org/10.1101/2023.03.01.530570 (2023).

Bell, C. G. et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 20, 249 (2019).

Article PubMed PubMed Central Google Scholar

Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 49, 359367 (2013).

Article PubMed CAS Google Scholar

Sziraki, A., Tyshkovskiy, A. & Gladyshev, V. N. Global remodeling of the mouse DNA methylome during aging and in response to calorie restriction. Aging Cell 17, e12738 (2018).

Article PubMed PubMed Central Google Scholar

Johansson, A., Enroth, S. & Gyllensten, U. Continuous aging of the human DNA methylome throughout the human lifespan. PLoS ONE 8, e67378 (2013).

Article ADS PubMed PubMed Central CAS Google Scholar

Zhou, W. et al. DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat. Genet. 50, 591602 (2018).

Article PubMed PubMed Central CAS Google Scholar

Long, H. K. et al. Epigenetic conservation at gene regulatory elements revealed by non-methylated DNA profiling in seven vertebrates. eLife 2, e00348 (2013).

Article ADS PubMed PubMed Central Google Scholar

Stadler, M. B. et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480, 490495 (2011).

Article ADS PubMed CAS Google Scholar

Xie, W. et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 153, 11341148 (2013).

Article PubMed PubMed Central CAS Google Scholar

Jeong, M. et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat. Genet. 46, 1723 (2014).

Article PubMed CAS Google Scholar

Zhang, X. et al. Large DNA methylation nadirs anchor chromatin loops maintaining hematopoietic stem cell identity. Mol. Cell 78, 506521.e506 (2020).

Article PubMed PubMed Central CAS Google Scholar

Ginno, P. A., Lott, P. L., Christensen, H. C., Korf, I. & Chedin, F. R-loop formation is a distinctive characteristic of unmethylated human CpG island promoters. Mol. Cell 45, 814825 (2012).

Article PubMed PubMed Central CAS Google Scholar

Williams, K., Christensen, J. & Helin, K. DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep. 13, 2835 (2011).

Article PubMed PubMed Central Google Scholar

Bartke, T. et al. Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell 143, 470484 (2010).

Article PubMed PubMed Central CAS Google Scholar

Hagarman, J. A., Motley, M. P., Kristjansdottir, K. & Soloway, P. D. Coordinate regulation of DNA methylation and H3K27me3 in mouse embryonic stem cells. PLoS ONE 8, e53880 (2013).

Article ADS PubMed PubMed Central CAS Google Scholar

Lindroth, A. M. et al. Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus. PLoS Genet. 4, e1000145 (2008).

Article PubMed PubMed Central Google Scholar

Wu, H. et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 329, 444448 (2010).

Article ADS PubMed PubMed Central CAS Google Scholar

Lu, A. T. et al. Universal DNA methylation age across mammalian tissues. Nat. Aging 3, 11441166 (2023).

Article ADS PubMed PubMed Central CAS Google Scholar

Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39, 237242 (2007).

Article PubMed PubMed Central CAS Google Scholar

Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232236 (2007).

Article PubMed CAS Google Scholar

Slieker, R. C., Relton, C. L., Gaunt, T. R., Slagboom, P. E. & Heijmans, B. T. Age-related DNA methylation changes are tissue-specific with ELOVL2 promoter methylation as exception. Epigenet. Chromatin 11, 25 (2018).

Article Google Scholar

Teschendorff, A. E. et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 20, 440446 (2010).

Article PubMed PubMed Central CAS Google Scholar

Widschwendter, M. et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157158 (2007).

Article PubMed CAS Google Scholar

Zheng, S. C., Widschwendter, M. & Teschendorff, A. E. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics 8, 705719 (2016).

Article PubMed CAS Google Scholar

Zhou, W. et al. DNA methylation dynamics and dysregulation delineated by high-throughput profiling in the mouse. Cell Genom. https://doi.org/10.1016/j.xgen.2022.100144 (2022).

Beerman, I. et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. Cell Stem Cell 12, 413425 (2013).

Article PubMed CAS Google Scholar

Dozmorov, M. G. Polycomb repressive complex 2 epigenomic signature defines age-associated hypermethylation and gene expression changes. Epigenetics 10, 484495 (2015).

Article PubMed PubMed Central Google Scholar

Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013).

Article PubMed PubMed Central Google Scholar

Lu, R. J. et al. Multi-omic profiling of primary mouse neutrophils predicts a pattern of sex and age-related functional regulation. Nat. Aging 1, 715733 (2021).

Article PubMed PubMed Central Google Scholar

Luo, C., Hajkova, P. & Ecker, J. R. Dynamic DNA methylation: In the right place at the right time. Science 361, 13361340 (2018).

Article ADS PubMed PubMed Central CAS Google Scholar

Minteer, C. et al. Tick tock, tick tock: mouse culture and tissue aging captured by an epigenetic clock. Aging Cell 21, e13553 (2022).

Article PubMed PubMed Central CAS Google Scholar

Mozhui, K. & Pandey, A. K. Conserved effect of aging on DNA methylation and association with EZH2 polycomb protein in mice and humans. Mech. Ageing Dev. 162, 2737 (2017).

Article PubMed PubMed Central CAS Google Scholar

Rozenblit, M. et al. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clin. Epigenet. 14, 30 (2022).

Article CAS Google Scholar

Ying, K. et al. Biolearn, an open-source library for biomarkers of aging. Preprint at bioRxiv https://doi.org/10.1101/2023.12.02.569722 (2023).

Ying, K. et al. ClockBase: a comprehensive platform for biological age profiling in human and mouse. Preprint at bioRxiv https://doi.org/10.1101/2023.02.28.530532 (2023).

Chen, C. C., Lim, C. Y., Lee, P. J., Hsu, A. L. & Ching, T. T. S-adenosyl methionine synthetase SAMS-5 mediates dietary restriction-induced longevity in Caenorhabditis elegans. PLoS ONE 15, e0241455 (2020).

Article PubMed PubMed Central CAS Google Scholar

Hahn, O. et al. Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism. Genome Biol. 18, 56 (2017).

Article PubMed PubMed Central Google Scholar

Petkovich, D. A. et al. Using DNA methylation profiling to evaluate biological age and longevity interventions. Cell Metab. 25, 954960.e956 (2017).

Article PubMed PubMed Central CAS Google Scholar

Browder, K. C. et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nat. Aging 2, 243253 (2022).

Article PubMed CAS Google Scholar

Chondronasiou, D. et al. Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming. Aging Cell 21, e13578 (2022).

Article PubMed PubMed Central CAS Google Scholar

Cipriano, A. et al. Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming. Nat. Aging https://doi.org/10.1038/s43587-023-00539-2 (2023).

Ocampo, A. et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 167, 17191733.e1712 (2016).

Article PubMed PubMed Central CAS Google Scholar

Sarkar, T. J. et al. Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. Nat. Commun. 11, 1545 (2020).

Article ADS PubMed PubMed Central CAS Google Scholar

Arneson, A. et al. A mammalian methylation array for profiling methylation levels at conserved sequences. Nat. Commun. 13, 783 (2022).

Article ADS PubMed PubMed Central CAS Google Scholar

Ludwin, S. K. Proliferation of mature oligodendrocytes after trauma to the central nervous system. Nature 308, 274275 (1984).

Article ADS PubMed CAS Google Scholar

Horvath, S. et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 13, R97 (2012).

Article PubMed PubMed Central CAS Google Scholar

Seale, K., Horvath, S., Teschendorff, A., Eynon, N. & Voisin, S. Making sense of the ageing methylome. Nat. Rev. Genet. 23, 585605 (2022).

Article PubMed CAS Google Scholar

Simpson, D. J. et al. Region-based epigenetic clock design improves RRBS-based age prediction. Aging Cell 22, e13866 (2023).

Article PubMed PubMed Central CAS Google Scholar

Youn, A. & Wang, S. The MiAge calculator: a DNA methylation-based mitotic age calculator of human tissue types. Epigenetics 13, 192206 (2018).

Article PubMed PubMed Central Google Scholar

Koldobskiy, M. A., Camacho, O., Reddy, P., Belmonte, J. C. I. & Feinberg, A. P. Convergence of aging- and rejuvenation-related epigenetic alterations on PRC2 targets. Preprint at bioRxiv https://doi.org/10.1101/2023.06.08.544045 (2023).

Read more:
PRC2-AgeIndex as a universal biomarker of aging and rejuvenation - Nature.com

Posted in Epigenetics | Comments Off on PRC2-AgeIndex as a universal biomarker of aging and rejuvenation – Nature.com

Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment…

Posted: July 21, 2024 at 2:38 am

Chula Medicine in collaboration with the Department of Thai Traditional and Alternative Medicine and Gastroenterologists from local medical schools proves that Thai curcumin can help treat dyspepsia as effectively as antacids, and is poised to push Thai curcumin to the global marketplace.

Many people may have experienced bloating, pain, tightness, nausea, and heartburn from dyspepsia, which is very common nowadays. To relieve the symptoms, many people adjust their lifestyle and habits, while taking antacids continuously. Others turn to Thai herbs such as curcumin. But the important questions are, Can curcumin replace antacids in treating dyspepsia? How to use it? Should it be used in combination with modern drugs? Are there any side effects?"

Associate Professor Dr. Krit Pongpirul, M.D., Director and Founder of the Center of Excellence in Preventive and Integrative Medicine (CE-PIM)

To address these questions, a team of experts led by Associate Professor Dr. Krit Pongpirul, M.D., Director and Founder of the Center of Excellence in Preventive and Integrative Medicine (CE-PIM), Faculty of Medicine, Chulalongkorn University designed a study to test the effectiveness of Thai curcumin capsules subsidized by the Government Pharmaceutical Organization compared to modern antacids.

Curcuminoids are effective as a pain reliever, antiseptic, and anti-inflammatory drug, but not the same as curcumin as in Turmeric. The dried and ground herb contains curcuminoids and other substances, including volatile oil.

The clinical study was carried out from June 2019 until April 2020 on 151 volunteers who were dyspepsia (early stage) patients but tested negative for H. pylori. The findings conclude that curcumin and omeprazole have no discernable differences in their effects in treating dyspepsia and that the combination of the two drugs has no increased therapeutic benefit. Also, no serious side effects have been reported from continuous intake of curcumin.

With proven results, the team is preparing to push the curcumin pill to the global market under the ThaiCureMin brand name. In the future, the team plans to find farmers and organic sources of turmeric that can be traced from upstream to downstream to increase consumer value and confidence. Moreover, the team will measure the essential oils in curcumin to see what substances they contain and in what quantities.

Read the full article at https://www.chula.ac.th/en/highlight/159854/

Read more:
Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment...

Posted in Integrative Medicine | Comments Off on Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment…

SKIMS Signs MoU with CCRUM for joint research collaboration – Rising Kashmir

Posted: July 21, 2024 at 2:38 am

Srinagar, July 19: Sher-i -Kashmir Institute of Medical Science recorded a significant moment as SKIMS and Central Council for Research in Unani Medicine (CCRUM) Ministry of Ayush, Government of India signed MOU (Memorandum of understanding) for joint research collaboration in presence of Director SKIMS, Dr. M Ashraf Ganie and Dr. N Zaheer Director General CCRUM, Dean Medical Faculty SKIMS Prof. Shariq R. Masoodi, Medical Superintendent SKIMS Dr. Farooq A Jan, Designate Nodal Officer for collaboration at SKIMS, Prof. Muzaffar Maqsood wani from the Department of Nephrology SKIMS and many other faculty members and senior officers from SKIMS & CCRUM. Director SKIMS Dr. M Ashraf Ganie welcomed the D.G, CCRUM Dr. N. Zaheer and other dignitaries. He expressed gratitude to D.G CCRUM Dr.N.Zaheer for reaching at the SKIMS for a joint collaboration to work in crucial area of research indigenous medicine integrated into allopathy. Dr. Ashraf while remarking on contribution of Dr. Zaheer as a luminary in his field said this new initiative of integrative program where allopathic & traditional medical practices will supplement each other will also explore strength & weaknesses of each field for very positive outcomes. He said the joint collaboration will work on a defined mechanism through Steering Committee and Core committee on various areas outlined in MOU, including Joint projects, educative programs and other exchange programs. Besides, the significant focus on areas of chronic diseases such as migraine, epilepsy, spondylosis and many more where allopathic practice are not successful to explore better interventions. He further added that the event has a added significance as the two key Institutions are coming together for efficient convergence of two different streams of medicine. A herbal garden of medicinal plants will soon be reality in SKIMS, for that land has been identified, he added. Dr. N Zaheer DG, CCRUM said the joint collaboration will undoubtedly yield positive results to benefit public health. He said the collaboration will help in optimum utilization of resources and expertise and prove beneficial and strengthen the integration of Ayush with mainstream medicine in areas of research, education and awareness at tertiary care. SKIMS being the premier tertiary care Institute will play a significant role through this collaboration, he added. While mapping the role of Integrative medicine in future he said this collaborative program at SKIMS will frame a bigger role in integrating Ayush with mainstream medicine. He assured all the support to the SKIMS for exploring new areas and defining treatment modalities under the integrative program including funding some important projects. Dr. Shariq R. Masoodi, Dean of the Medical Faculty at SKIMS, remarked that integrating AYUSH with modern medicine at SKIMS Srinagar has the potential to offer valuable opportunities for patient care and research. However, there is need of addressing the challenges of standardization, regulation, and integration are crucial for successful implementation. Commenting on the MoU (Memorandum of Understanding) between SKIMS and CCRUM, Dr. Masoodi said the collaboration would be beneficial and provide an opportunity to learn from each others strengths and weaknesses. The faculty from the SKIMS recorded their valuable suggestions and inputs to lead this collaboration successfully and congratulated Director SKIMS for this fruitful venture for greater contribution in public health. It is pertinent to mention that CCRUM as the apex government organization for research in Unani Medicine has been engaged in conducting scientific research on the applied as well as fundamental aspects of Unani system of medicine.

Read more:
SKIMS Signs MoU with CCRUM for joint research collaboration - Rising Kashmir

Posted in Integrative Medicine | Comments Off on SKIMS Signs MoU with CCRUM for joint research collaboration – Rising Kashmir

SOTIO partners with Biocytogen to expand ADC pipeline – European Biotechnology News

Posted: July 21, 2024 at 2:37 am

Under the agreement, Prague-based SOTIO Biotech AS will pay up to US$325.5m biobucks to use Biocytogens RenLite antibody discovery platform to design bispecific antibody drug conjugates (ADC) that home in on selected different cancer targets. The amount of the upfront payment was not specified. Biocytogen will be eligible to receive single-digit royalties on net sales on a product-by-product basis. SOTIO will be responsible for preclinical and clinical development, manufacturing, and commercialisation of the ADC products.

The contract also grants SOTIO the option to license multiple fully human bispecific antibodies generated with Biocytogens proprietary RenLite platform, which SOTIO will use to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumours. The agreement also includes an option for SOTIO to leverage Biocytogens proprietary ADC platform. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice (RenMab/RenLite/RenNano/RenTCR-mimic) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice licensing projects have been established around the globe

This agreement with Biocytogen complements our existing collaborations with Synaffix, LegoChem, and NBE-Therapeutics, providing SOTIO with access to fully human antibodies from Biocytogens state-of-the-art in vivo discovery platform, said Martin Steegmaier, CEO of SOTIO. With the first targets for a bispecific program already selected, we are well-positioned to expand our ADC pipeline and the therapeutic possibilities for patients with solid tumours.

The eight RenMice platforms can be used to discover fully human antibodies with high affinity, low immunogenicity, and favourable developability.

Currently, the SOTIO pipeline includes three clinical-stage programs: SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumours; and SOT201, a next-generation PD-1-targeting immunocytokine. SOTIO is a member of the PPF Grouphttps://european-biotechnology.com/latest-news/pff-group-nv-acquires-stake-in-autolus-therapeutics/.

The rest is here:
SOTIO partners with Biocytogen to expand ADC pipeline - European Biotechnology News

Posted in Biotechnology | Comments Off on SOTIO partners with Biocytogen to expand ADC pipeline – European Biotechnology News

Biotechnology Market: Surging Investments and Infrastructure Development Propel 13.9% CAGR by 2031| SkyQuest Technology – PR Newswire

Posted: July 21, 2024 at 2:37 am

WESTFORD, Mass., July 18, 2024 /PRNewswire/ -- According to SkyQuest, the global Biotechnology Marketsize was valued at USD 1.21 Trillion in 2022 and is poised to grow from USD 1.38 Trillion in 2023 to USD 3.90 Trillion by 2031, growing at a CAGR of 13.9% during the forecast period (2024-2031).

Biotechnology is a diversified, innovative industry that uses organisms, biological systems, or their products to modify or develop processes and by-products to produce health-related products and treatments.

Biotechnology and related products are required to meet established regulatory guidelines and standards. The major federal agencies in the US responsible for administering the required standards are the Animal and Plant Health Inspection Service (APHIS), US. The Coordinated Framework for the Regulation of Biotechnology outlines a government framework for evaluating products developed using modern biotechnology. This provision is based on existing laws developed to protect public health and the environment.

Download a detailed overview:

https://www.skyquestt.com/sample-request/biotechnology-market

Biotechnology Market Overview:

Report Coverage

Details

Market Revenue in 2023

USD 1.38 Trillion

Estimated Value by 2031

USD 3.90 Trillion

Growth Rate

Poised to grow at a CAGR of 13.9%

Forecast Period

20242031

Forecast Units

Value (USD Trillion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

Type, Product, Technology, Application and Region

Geographies Covered

North America, Europe, Asia Pacific, Middle East & Africa, Latin America

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Growth in Nanobiotechnology

Key Market Drivers

Growing Research and Development of Tissue Culture and Cell Engineering

Segments covered in Biotechnology Market are as follows:

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/biotechnology-market

DNA Sequencing Holds a Dominant Position in the Biotechnology Market Owing to the Rising Adoption of Advanced Techniques

DNA sequencing occupies a dominant position in the biotechnology market, accounting for about 17.43% by 2023. This growth is due to two main factors: cheaper sequencing costs and the adoption of advanced techniques and government funding also plays an important role. A grant like the one awarded by the NIH (National Institutes of Health) that may be $10.7 million by May 2021, directed toward understanding the genetics of Alzheimer's disease, is an example of this kind of funding. Such funding fuels research and it opens new applications for DNA sequencing, ideal for various diseases.

The nanobiotechnology segment is poised to surge from 2024 to 2031. Two main factors fuel this growth: more nanomedicine approvals and remarkable growth in the sector. In addition, nanoparticles for diagnosis are revolutionizing disease diagnosis, allowing for comparative diagnosis and personalized medicine simultaneously. Tissue technology and regenerative medicine is growing due to government and private investments, high healthcare spending, and the rise of established and new players.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/biotechnology-market

Healthcare Industry Led the Market Owing to the Enhance Revenue Generation

The healthcare industry led the market and is expected to register a compound annual growth rate (CAGR) of 13.9% throughout the forecast period. Healthcare biotechnology has proven its importance, emerging as the biggest revenue generator by 2020. Biotechnology innovation has given birth to new sectors of the economy, driven largely by small start-ups and interagency collaboration as they are also being used for further treatments to improve the sector. For example, in April 2020, Amgen and Adaptive Biotechnologies collaborated to identify and develop anti-SARS-CoV-2 vaccines using Adaptive's proprietary immunotherapy platform to find antibodies that neutralize viruses This agreement is expected this will significantly increase revenue in this sector.

The food and agriculture sector ranks second in the market. The tools used in agriculture have evolved rapidly, including micropropagation, tissue culture, molecular breeding, marker-assisted selection, genetic engineering, genetically modified (GM) crops, molecular diagnostic technologies, and new genetics providing a comprehensive understanding of plant biology. Moreover, the global adoption of GM crops is expected to boost the segments. GM crops, especially herbicide-resistant and pest-resistant seeds, have become increasingly popular, boosting the agricultural industry.

Biotechnology Market: Shaping the Future of Innovation

The market is at the forefront of scientific and technological innovation, poised to deliver transformative solutions to some of the world's most pressing challenges. Focusing on areas such as healthcare, agriculture and environmental sustainability, biotechnology is driving progress through cutting-edge research and development.

Advances in genetic engineering, bioinformatics and bioprocessing technologies are fueling the growth of this market. Specialty areas such as personalized medicine, gene therapy and sustainable agricultural practices can benefit from these innovations, delivering results and efficiency.

Strategic dialogue, investment in R&D and a favorable regulatory environment are going to drive the biotechnology market. Companies are constantly exploring new frontiers, from CRISPR-based gene editing to biotechnology, to unlock and address new possibilities.

Related Reports:

Biotechnology & Pharmaceutical Services Outsourcing Market

Plant Biotechnology Services Market

Marine Biotechnology Market

Genomics Market

Digital Health Market

About Us:

SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Contact:Mr. Jagraj Singh SkyQuest Technology 1 Apache Way, Westford, Massachusetts 01886 USA (+1) 351-333-4748 Email: [emailprotected] Visit Our Website:https://www.skyquestt.com/

Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg

SOURCE SkyQuest Technology

Read this article:
Biotechnology Market: Surging Investments and Infrastructure Development Propel 13.9% CAGR by 2031| SkyQuest Technology - PR Newswire

Posted in Biotechnology | Comments Off on Biotechnology Market: Surging Investments and Infrastructure Development Propel 13.9% CAGR by 2031| SkyQuest Technology – PR Newswire

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above Fifty Day Moving Average of $59.28 – Defense World

Posted: July 21, 2024 at 2:37 am

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB Get Free Report)s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $59.28 and traded as high as $65.21. ProShares Ultra Nasdaq Biotechnology shares last traded at $65.21, with a volume of 17,865 shares changing hands.

The stock has a 50 day simple moving average of $59.28 and a 200 day simple moving average of $57.27.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 3rd. Shareholders of record on Wednesday, June 26th were paid a $0.2648 dividend. This represents a $1.06 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date of this dividend was Wednesday, June 26th. This is a boost from ProShares Ultra Nasdaq Biotechnologys previous quarterly dividend of $0.04.

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each days returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Continued here:
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above Fifty Day Moving Average of $59.28 - Defense World

Posted in Biotechnology | Comments Off on ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above Fifty Day Moving Average of $59.28 – Defense World

Page 24«..1020..23242526..3040..»